Drug
Topiramate
Topiramate: highest development phase Post-Market, developed by Endo, Johnson & Johnson, Teva. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Endo, Johnson & Johnson, Teva
Trials
| Drug | Phase | Indication |
|---|---|---|
| topiramate NCT00846495 | Post-Market | Migraine |
| Topiramate NCT00035230 | Phase 3 | Bipolar Disorder |
| Topiramate 25 mg Capsules NCT00905346 | Phase 1 | Healthy |
Latest
No recent events.
Follow Topiramate on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.